Subscribe To
Fortive buying ea elekro-automatik for $1.45b
Fortive Corp. FTV, -1.21% said Monday it will pay $1.45 billion net of $215 million of tax benefits to buy EA Elektro-Automatik Holding GmbH, a suppli...
October 23, 2023, 8:46 am
Should first trust value line dividend etf (fvd) be on your investing radar?
Launched on 08/19/2003, the first Trust Value Line Dividend ETF (FVD) is a passively managed exchange t...
October 23, 2023, 7:31 am
Should first trust capital strength etf (ftcs) be on your investing radar?
Launched on 07/06/2006, the first Trust Capital Strength ETF (FTCS) is a passively managed exchange tra...
October 23, 2023, 7:31 am
Big tech is battling to put ai on your pc, laptop and smartphone
It's clear that the wave of artificial intelligence is driving the technology sector today. Listen to any earnings call or watch any product announcem...
October 23, 2023, 7:18 am
Fx option expiries for 23 october 10am new york cut
There are quite a number to take note of for the day, as highlighted in bold.the first being for EUR/US...
October 23, 2023, 5:41 am
Kbwb: the hammering of banking stocks presents an opportunity
The article evaluates the Invesco KBW Bank ETF as an investment option at its current market price. I shifted to a bullish stance on the banking secto...
October 23, 2023, 3:31 am
Australian pm albanese confirms he will meet with communist party chair xi in china in nov
Australian Prime Minister Albanese will visit China from November 4 to 7Will meet with Chinese Communist Party Chairman Xi Jinping Albanese will becom...
October 23, 2023, 2:43 am
Gold pulls back from haven-driven highs
Gold was lower in early Asian trade, pulling back after climbing above $2,000 an ounce last Friday for the fir...
October 23, 2023, 1:59 am
Pro-bitcoin javier milei trails as argentina’s presidential election goes to run-off
Pro-Bitcoin (BTC) presidential candidate Javier Milei failed to secure victory in the first round of th...
October 23, 2023, 1:59 am
Japan’s ruling ldp won 1 seat and lost 1 seat in sunday’s diet by-elections
There were two by-elections in Japan on Sunday:one for a lower house seatone for an upper house seatthe ruling Liberal Democratic Party won the lower ...
October 23, 2023, 12:35 am
Mallinckrodt to present data on terlivaz® (terlipressin) for injection in adult patients with hepatorenal syndrome (hrs) at the american college of gastroenterology (acg) annual scientific meeting
– Findings from two clinical studies and one health economic database analysis provide insight into HRS treatment outcomes with TERLIVAZ,1 patients'...
October 22, 2023, 3:05 pm
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in ...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in ...
October 22, 2023, 10:01 am